# Inhaled DMT for Major Depressive Disorder

> **NCT07562191** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Universidade Federal do Rio Grande do Norte** · enrollment: 140 (estimated)

## Conditions studied

- MDD
- Major Depressive Disorder (MDD)
- Major Depression
- Suicidal Ideation
- Suicide

## Interventions

- **DRUG:** N,N-Dimethyltryptamine (15 mg + 60 mg)
- **DRUG:** N,N-Dimethyltryptamine (1 mg + 4 mg)

## Key facts

- **NCT ID:** NCT07562191
- **Lead sponsor:** Universidade Federal do Rio Grande do Norte
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07562191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07562191, "Inhaled DMT for Major Depressive Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07562191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*